Outset Medical Q3 revenue rises 14% to $33.6 million; net loss narrows
Outset Medical reported third quarter 2026 revenue of $33.6 million, up 14% from the prior-year period, and a net loss of $14.7 million, compared with $17.8 million a year earlier. The company reiterated its 2026 revenue guidance of $125 million to $130 million, so shareholders see higher sales and a smaller loss, with no change to the outlook.
Key points
- Q3 2026 revenue was $33.6 million, up 14% from $29.4 million in Q3 2025; product revenue rose 15% and service and other revenue rose 12%.
- Net loss was $14.7 million, or $0.78 per share, versus $17.8 million, or $1.00 per share, in Q3 2025.
- Gross margin was 40.7%, up from 39.4% a year earlier; non-GAAP gross margin was 40.8%.
- Total cash, cash equivalents, short-term investments and restricted cash was $140.7 million at September 30, 2026, and the company reiterated 2026 revenue guidance of $125 million to $130 million.
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.